William S. Richmond

Partner Healthcare & Life Sciences Regulatory

Washington, D.C. +1 202 389 3222

William S. Richmond

Overview

Will Richmond is a corporate healthcare partner in the Washington, D.C., office of Kirkland & Ellis LLP. Will provides legal counsel to private equity funds, venture capital, and public companies. He also advises on a broad range of issues including corporate transactions, federal healthcare fraud and abuse laws such as the Anti-Kickback Statute and the Stark Law, physician employment agreements, HIPAA, compliance programs, corporate practice of medicine, and transactions involving state and federal tax-exempt entities. He has structured and negotiated acquisitions and dispositions of healthcare providers and suppliers by private equity funds, hospital mergers and acquisitions, affiliations and joint ventures. He also advises clients on healthcare regulatory matters incident to restructurings, bankruptcies, and liability management transactions.

Will is regularly called upon to advise clients on healthcare regulatory matters across a broad spectrum of industries including healthcare providers, pharmacies, revenue cycle management companies, medical device companies, drug manufacturers, contract development and manufacturing organizations, non-profit healthcare providers, infusion therapy providers, and other healthcare providers and entities.

Healthcare Providers

  • VSP Vision in its acquisition of Eyemart Express from FFL Partners and Leonard Green & Partners
  • Cressey & Company in the acquisition of HealthDrive, a provider of clinical services to patients residing in long-term care facilities, from Bain Capital Double Impact
  • TPG's The Rise Fund in its investment in Banyan Treatment Centers, a provider of substance use disorder and mental health services
  • Vertava Health of Mississippi, a provider of addiction treatment and mental health services, in its sale to Bradford Health Services
  • Percheron Capital-backed Animal Dermatology Group in its acquisition of Animal Dermatology and Allergy Specialists
  • Seattle Reproductive Medicine, a fertility center, in its sale to Pinnacle Fertility

Healthcare Technology

  • GTCR, alongside Avryo Health Services, in its investment in 7to7 Dental, a dental service organization
  • Trinity Hunt Partners in its investment in Coker, a healthcare advisory firm
  • GTCR-backed RevSpring, a provider of communication and payment solutions, in its sale to Frazier Healthcare Partners 
  • Olympus Partners in the sale of Soliant, a provider of workforce solutions in K-12 school districts and healthcare facilities, to The Vistria Group
  • Stone Point Capital-backed Tivity Health in its acquisition of Burnalong, a digital health, wellness and fitness platform
  • EW Healthcare Partners in its acquisition of Enercon Technologies, a provider of electronic product development and manufacturing services
  • Vesey Street Capital Partners in its sale of QualityMetric, a provider of tools and technology that measure health from the patient's point of view
  • Olympus Partners in its acquisition of EyeSouth Partners, an eye care management services organization, from Shore Capital Partners
  • Francisco Partners in its acquisition of the healthcare data and analytics assets from IBM (NYSE: IBM) that are currently part of the Watson Health business
  • Thoma Bravo in its $6.9 billion acquisition of SailPoint Technologies (NYSE: SAIL), enterprise identity security provider
  • Bain Capital Private Equity in its investment in CitiusTech, a provider of technology and consulting services to healthcare and life sciences companies

Life Sciences

  • Owens & Minor (NYSE: OMI) in its pending $1.36 billion acquisition of Rotech Healthcare, a provider of home medical equipment
  • Avista Healthcare Partners in its acquisition of Trillium Health Care Products, a contract development and manufacturing organization of branded over-the-counter products, from New Water Capital
  • Trilantic North America in its investment in SOFIE Biosciences, a Positron Emission Tomography (PET) radiopharmacy and contract development and manufacturing organization (CDMO)
  • Silver Oak backed-Integrated Oncology Network, a provider of oncology services, in its pending $1.115 billion sale to Cardinal Health (NYSE: CAH)
  • EQT-led consortium in the £4.5 billion acquisition of Dechra Pharmaceuticals (LSE: DPH), a provider of specialist veterinary pharmaceuticals and related products
  • Nordic Capital in its acquisition of IntegriChain, a platform for pharma commercialization and market access, from Accel-KKR
  • Bristol Myers Squibb (NYSE: BMY) in its $5.8 billion acquisition of Mirati Therapeutics (NASDAQ: MRTX), a commercial stage research and development biotechnology company
  • Owens & Minor (NYSE: OMI) in its $1.6 billion acquisition of Apria (NASDAQ: APR), a provider of integrated home healthcare equipment and related services
  • EQT-backed Recipharm in its acquisition of Arranta Bio, an advanced therapy medicinal products (ATMPs) contract development and manufacturing organization (CDMO), from Ampersand Capital Partners
  • EQT-backed Recipharm in its acquisition of Vibalogics, a virotherapy contract development and manufacturing organization (CDMO), from Ampersand Capital Partners
  • The Jordan Company in its investment in WEP Clinical, a specialist pharma services company that works with drug developers to help patients and physicians gain early access to medicines

Nelson Mullins Riley & Scarborough 

Ernst & Young

Will provides pro bono legal counsel to individuals seeking Special Immigrant Juvenile classification. 

More

Credentials

Admissions & Qualifications

  • District of Columbia
  • New York

Education

  • American University School of International ServiceM.A., International Affairs2020
  • New York University School of LawLL.M., Taxation2018
  • American University Washington College of LawJ.D.cum laude2017
    Editor-in-Chief, National Security Law Brief
  • Clemson UniversityB.A., Political Science2014